No, this isn't for your typical infant who drools everywhere.
The U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.
Drooling is normal in infants. But a significant proportion of the
developmentally disabled population experiences drooling caused
primarily by neuromuscular dysfunction that makes it hard to swallow.
Cuvposa reduces drooling by lowering the volume of saliva produced.
You can learn more here.
Cuvposa (glycopyrrolate) Oral Solution is marketed by Shionogi Pharma Inc. of Osaka, Japan.
Post a Comment